Latest Tuberculosis treatment Stories
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection.
Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine.
In 2010 the World Health Organization (WHO) estimated there were 290,000 cases of multi-drug resistant tuberculosis globally. Now a new medication attempts to slash those numbers.
A joint Innovation Summit seeks to find solutions for identified barriers to treating tuberculosis. Boston, MA (PRWEB) May 17, 2012 Leading global public
Today, the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC) publish their jointly developed European Union Standards for Tuberculosis Care (ESTC).
A two-drug combination is one of the most promising advances in decades for the treatment of tuberculosis (TB) — a disease that kills 2 million people annually — a scientist reported today at the 243 National Meeting & Exposition of the American Chemical Society (ACS).
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.